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NMR spectra of these new compounds.  
Abstract. The selective manipulation of Hyp customizable 
units in DKP substrates allows the generation of a rigid 
scaffold with four tailor-made chains which are spatially-
orientated. The key step is a domino radical scission-
oxidation process which allows the generation of N-
substituted DKPs. 
The versatility of this methodology to produce scaffolds in 
high optical purity for material and drug discovery is 
described herein 
Keywords: chemoselectivity, domino reactions, organic 
synthesis, peptides, sustainable chemistry 
 
Introduction 
The site-selective modification of peptides through 
scission of “customizable units” such as Hyp, Ser/Thr, 
or Glu, and further manipulation of the resulting 
chains, has allowed the introduction of unnatural 
amino acids with a diversity of functionalized 
chains.
[1,2]
 These chains can present groups for 




The interaction with receptors is favored when a 
rigid scaffold orientates the functionalized chains in 
the appropriate directions. The diketopiperazine 
(DKP) scaffold (Figure 1) seemed particularly 
promising,
[4]
 since it is readily formed from 
inexpensive materials, it can be functionalized with 
four different chains, and remarkably, the chains on 
C- would be oriented in opposite directions to the 
N-substituents (structure 1).
[5,6]
 In this way, multiple 
interactions with different biological receptors or 
with different residues in a certain active center could 
be achieved. The cyclic dipeptides could also be 
attached to form dimers, oligomers or polymers 
(structure 2), increasing the number of functional 
groups.
[7,8]
 The formation of DKP-containing 
polymers has scarcely been explored, particularly the 
use of tetrasubstituted DKPs as polymer units as 
shown in structure 2. 
We have recently been interested in peptide-
derived scaffolds that can carry drugs or medical 
probes through biological membranes, in particular 
bacterial membranes.
[8,9]
 It is known that peptides 
with cationic residues strongly interact with bacterial 
membranes, which are negatively-charged.
[10]
 Since 
eukaryotic membranes are almost neutral, their 
interaction with the cationic peptides is reduced. If 
the peptides combine cationic and hydrophobic 
residues in an appropriate ratio, promising 
antimicrobials can result, displaying good target 
selectivity.
[10,11]
 Based on this information, it would 
be interesting to design DKP scaffolds (1, Figure 1) 
with a combination of cationic and hydrophobic 
chains, whose spatial orientation favored cell 
penetration. 
 
Figure 1. DKP scaffolds for biomedical applications.  
Natural and synthetic DKPs are known to display 
antimicrobial
[4,12]
 and quorum quenching activity,
[4,13]
 
but most are N-unsubstituted or N-monosubstituted 
(often N-methylated). Recently synthetic 
antimicrobial DKPs with two cationic and two 
hydrophobic residues were reported by Svenson et al 
(compounds 1a and 1b, Figure 2).
[14]
 In this work, 
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only tetrasubstituted DKPs with bulky N-substituents 
such as the 4-phenyl benzyl group displayed a potent, 
broad-spectrum antibacterial activity. Interestingly, 
the most active compounds 1a and 1b would match 
the model scaffold 1, with the two cationic 
substituents as cell-penetrating α-chains X and Y. 
 
Figure 2. Reported DKP scaffolds with potent antimicrobial 
activity [Svenson et al, ref. 14].  
The DKPs 1a/1b presented two identical cationic 
and two identical hydrophobic units. In contrast, this 
communication will address the synthesis of DKP 
scaffolds with four different chains, which could be 
tailored to be cationic or hydrophobic residues. 
The synthesis of such scaffolds is not simple. In 
spite of the ready formation of DKP rings in usual 
peptides,
[4]
 and even N-methyl substituted cyclic 
dipeptides,
[15]
 when other N-alkyl substituted DKPs 
are required, the synthesis is more complex.
[16,17]
 The 
formation of tetrasubstituted DKPs often proceeds in 
low yields, with long reaction times or epimerization 
problems.
[4,16-17]
 In the case of the DKPs 1a/1b, a 
strong base and a very reactive electrophile (4-phenyl 
benzyl bromide) were used to introduce the bulky 
hydrophobic residues at both N-positions.
[14a]
  
In another interesting work, Luthman et al reported 
that the cyclization of terminal N-substituted 
dipeptides to the desired tetrasubstituted DKPs failed. 
Therefore, an alternative route was developed, where 
a trisubstituted DKP was synthesized, using high 
temperatures under microwave irradiation, and then 
the last N-substituent was introduced using highly 
reactive electrophilic reagents (propargyl, allyl or 
benzyl bromides, an alkyl iodide).
[16]
 These examples 
are representative of the difficulties found by 
different groups to produce tetrasubstituted DKPs.
[17]
 
In addition, when non-natural residues are 
involved, the synthetic challenge increases. We report 
a method in which a single DKP substrate with two 
customizable Hyp units can afford a library of DKP 
scaffolds with four different chains for biomedical 
SAR studies, including bulky N-alkyl substituents. 
Other advantages are the mild reaction conditions, 
and the preservation of the stereochemistry of the 
initial Hyp units. 
[18]
 
Finally, we will comment on the synthesis of 
tetrasubstituted DKP units as polymer substrates. As 
commented before, there are few reports on the 




penetrating peptidomimetics for effective DNA 
delivery were described.
[8]
 These peptidomimetics 
were formed from DKP units containing a cationic 
lysine and an anionic aspartic acid. Their lateral 
chains were attached by peptide bonds to form the 
polymer backbone. However, the formation of 
polymers where the DKP units are bound by an inert 
linker, while the cationic and hydrophobic residues 
are free for interaction with biological targets, would 
be a novel approach for the synthesis of antimicrobial 
materials. The formation of tetrasubstituted 
monomers for metathesis-driven polymerization will 
be described herein. 
Results and Discussion 
Initially, we studied the scission of a model 
substrate 3 (Table 1), using a domino process in 
which the alcohol was first transformed into an O-
radical (not shown), which underwent oxidative 
radical scission of the C4C5 bond, forming an 
acyliminium ion 4, which was trapped by acetate ions 
from the reagents to give the scission product 5.
[19]
 











1 DIB (1.5) 0.5 2 h   c.m.
[c]
 
2 LTA (1.5) 0.5 2 h   c.m. 
3 DIB (1.5) 0.3 2 h   c.m. 
4 DIB (2) 0.3 30 min   15 
5 DIB (2) 0.8 2 h   12 
6 DIB (4) 1.5 20 min   60 
[a]
DIB, I2, h (visible), DCE, reflux; DIB = (diacetoxyiodo) 
benzene; LTA = lead tetraacetate; 
[b]
Yield for products 
purified by chromatography. 
[c]
c.m. = complex mixture. 
The process was optimized as shown in Table 1, 
using different scission reagents (DIB/I2, LTA/I2), 
reagent amounts, and reaction times. In all the cases, 
the solvent was DCE and the mixture was irradiated 
with visible light.
[1,20]
 The best conditions (entry 6) 
used the diacetoxyiodobenzene (DIB)-iodine system 
(4 and 1.5 equivalents with respect to the DKP 
substrate), in refluxing DCE during 20 min. Smaller 
amounts of DIB (entries 3-5) or iodine (entries 1-5) 
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resulted in complex mixtures and/or low yields of 
product 5, probably because a longer reaction time 
was needed, which favoured side-reactions.  
As shown in Scheme 1, using the optimized 
conditions for the oxidative radical scission, 
simplified two-step scission-reductive amination 
process (to give products 8-12) and scission-
reduction process (yielding products 13 and 14) were 
implemented. 
 
Scheme 1. Modification of Hyp customizable units in DKP. 
The starting DKPs contained one or two 
customizable Hyp units (substrates 3 and 6, 
respectively). The fragmentation products 5 or 7 were 
not purified; after disappearance of the starting 
material, the reagents were deactivated by aqueous 
work-up, and the organic solvent was quickly 
evaporated. The crude residue was then treated under 
reductive amination or reduction conditions, to give 
products 8-14 in good global yields (Scheme 1).  
In the case of substrate 6, two customizable Hyp 
units were incorporated. Since one of them was 
protected with a benzyl group, the scission only took 
place with the unprotected Hyp residue. The yields 
were comparable to those obtained with substrate 3 (9 
vs.10 and 11 vs.12). 
The reductive amination can provide a variety of 
cationic residues, from precursors of primary amines 
(e.g. the readily deprotected dibenzylamino group in 
compound 8), to nitrogen heterocycles used in drugs 
(such as the morpholino group in compounds 9-10), 
and extended peptides (by ligation of amino acids or 
peptides, as in compounds 11 and 12).  
When substrate 3 was treated under the scission-
reduction protocol, two products 13 and 14 were 
formed (66% global yield for the two steps). Thus, 
the N-methoxymethyl derivative 13 was formed by 
substitution of the acetoxy group in compound 5 by 
the solvent (via an iminio intermediate), while 
compound 14 was obtained by hydrolysis of the 
acetate group and cleavage of the resulting 
hemiacetal. On larger reaction times, compound 13 
can be transformed into compound 14. 
The scission and subsequent chain modification 
was also studied with substrate 15 (header Table 2).  
Table 2. Modification of Hyp units in DKP substrate 15.  
 
entry Conditions A Products (yield)
[a]
 
1 Bn2NH, Et3N, DCE, 
26 ºC, 30 min; 
NaBH(OAc)3, 17 h 
17 (59%);  
R = CH2OAc 
X = CH2N(CH2Ph)2 
2 Morpholine, Et3N, 
DCE, 26 ºC, 30 min; 
NaBH(OAc)3, 17 h 
18 (68%) 
R = CH2OAc 
 
3 H-Hyp-OMe, Et3N, 
DCE, 26 ºC, 30 min; 
NaBH(OAc)3, 17 h 
19 (52%) 
R = CH2OAc 
 
4 NaBH4, MeOH,  
26 ºC, 15 h 
20 (57%) 
R = H,     X = 
CH2OH 





Yield for products purified by chromatography.  
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The diketopiperazine substrate 15 not only presents 
a flexible α-chain, but also an unprotected NH group, 
which could favour side-reactions. Therefore, the 
aldehyde intermediate 16 was not isolated, but 
quickly underwent transformation under a variety of 
conditions [A] (Table 2), to afford products 17-21. 
To our satisfaction, the scission and subsequent 
reductive amination reactions (entries 1-3) proceeded 
in similar yields as before, to afford products 17-19. 
However, the scission and reduction (entry 4) gave 
only the alcohol 20, in which cleavage of the 
intermediate N,O-acetal was observed. 
The aldehyde 16 also underwent a Horner-
Wadsworth-Emmons reaction (entry 5), to afford a 
homoglutamic derivative 21.[1b] The introduction of 
this chain allows the preparation of a variety of 
functionalized scaffolds, since it can be saponified 
and transformed into an anionic residue, or it can be 
transformed into esters and amides with different 
chains, including those containing fluorophores, 
branched amines, metal chelators or attached drugs. 
Finally, a selective double functionalization of 
DKP substrates was studied, using substrate 6 
(Scheme 2). As commented before, the scission only 
took place with the unprotected Hyp residue, and 
subsequent reductive amination afforded product 10. 
The second Hyp unit can then be deprotected and 
functionalized in a different way. The cleavage of the 
benzyl group of compound 10 by hydrogenolysis was 
studied under different conditions, including different 
catalysts (Pd/C and Pd(OH)2), amount of catalysts, 
solvents (MeOH, EtOAc, THF, etc), and hydrogen 
pressure (1-4 atm). The best results were obtained 
with the Pd/C system in AcOH. Under atmospheric 
pressure, a mixture of the N,O-acetal 22 (36%) and 
the N-methyl DKP 23 (28%) was obtained. When the 
reaction was carried out under higher hydrogen 
pressure (4 atm), the N-methyl derivative 23 was 
obtained as the sole product, in 67% yield. 
 
Scheme 2. Deprotection of the second customizable Hyp 
unit, for a second transformation cycle. 
The sequential modification of the two Hyp units 
to give a hydrophobic residue (homoGlu) and a 
cationic unit (4-aminohomoalanine) is shown in 
Scheme 3. Thus, substrate 6 underwent scission of 
the first, unprotected Hyp unit, and after aqueous 
work up and solvent removal, the crude reaction 
mixture underwent a Horner-Wittig-Emmons reaction 
to provide the homoglutamic derivative 24 in 53% 
global yield.  
 
Scheme 3. Sequential transformation of two Hyp 
customizable units, to give products with four different 
ring substituents. 
Then the second Hyp unit was deprotected by 
hydrogenolysis, accompanied by olefin reduction, to 
afford compound 25 and the N-methyl derivative 26. 
Compound 25 can be quantitatively transformed into 
product 26 by increasing hydrogen pressure to 4 atm. 
A second scission took place, followed by reductive 
amination, that transformed compounds 25 and 26 
into the DKP derivatives 27 and 28, respectively. 
The N,O-acetal can be further transformed into a 
diversity of N-substituents. Unlike other 
methodologies, where basic conditions and strong 
electrophiles are used to introduce the new chains, 
herein this step is carried out by addition of 
nucleophiles to the N,O-acetal at low temperature. 
Due to the mild conditions, DKP epimerization and 
other side-reactions are minimized. 
For instance, treatment of compound 27 with 
allyltrimethylsilane and TMSOTf at 0 
o
C provided 
the diolefinic compound 29 (Scheme 4) in good yield. 
The introduction of homoallylic N-substituents is 
particularly interesting, since intermolecular 
metathesis followed by reduction would generate 
dimeric or polymeric systems with DKP units 
connected by inert linkers.
[21]
 These systems would 
display many lateral chains for interaction with 
biological targets, which could enhance the 
bioactivity. On the other hand, the olefins can be 
extended (and/or “capped”) by intermolecular 
metathesis with other olefinic compounds. 
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As shown with monomer (29), a combination of 
cationic and hydrophobic residues can be 
implemented. Moreover, the cationic character of the 
final molecule, and thus its bioactivity, could be 
modulated by transforming the hydrophobic ester into 
esters or amides derived from hydroxyamines, 
diamines, branched amines and related groups. Other 
functional moieties could also be attached, such as 





Scheme 4. Preparation of tetrasubstituted monomers for 
metathesis-promoted polymerization. 
The DKP scaffolds 27-29 present four different 
spatially-oriented chains (Figure 3). Thus, according 
to MM2 energy minimization studies,
[22]
 the α-lateral 
chains are directed below the DKP plane, while the 
N-substituents (acetoxymethyl or allyl groups) are 
directed in and above the plane. In simple compounds, 
two chains could be used to interact with and cross 
biological membranes, while the other two chains can 
be used to shuttle conjugated drugs or probes or to 
provide likers in polymers. 
 
 
Figure 3. Tetrasubstituted DKP scaffolds for biomedical 
applications. MM2 for compounds (28, above) and (29). 
We are currently studying the introduction of other 
N-alkyl chains and the dimerization or 
oligorimerization of olefinic derivatives. The 
bioactivity results will be reported in due course. 
Conclusion 
The selective manipulation of Hyp customizable 
units in DKP substrates allows the generation of a 
rigid scaffold with four new, tailor-made chains 
which are spatially-orientated. The key step is a 
domino radical scission-oxidation process which 
allows the generation of N-substituted DKPs. The 
chains generated after the scission can be 
manipulated to afford either cationic or hydrophobic 
residues, as required in antimicrobial SAR studies. 
These compounds can be also used as monomer 
units for polymerization, displaying both 
hydrophobic and cationic chains. The preparation of a 
di-N-homoallylic substituted DKP for future 
metathesis-driven polymerization was illustrated. 
Remarkably, the bulky alkyl chains were introduced 
under mild conditions, by addition of nucleophiles to 
the intermediate N,O-acetals, at low temperatures. 
Thus, the tetrasubstituted DKP was obtained in good 
yield with high optical purity, meeting the 
requirements for antimicrobial assays.  
Experimental Section 
Experimental Details 
General Methods. Commercially available 
reagents and solvents were analytical grade or were 
purified by standard procedures prior to use. All 
reactions involving air- or moisture-sensitive 
materials were carried out under nitrogen atmosphere. 
The spray reagent for TLC analysis was a potassium 
permanganate solution [KMnO4 (10 g), K2CO3 (66.7 
g) and NaOH (0.85 g) were dissolved in water (1L)]. 
Once sprayed, the TLC was heated until development 
of color.  
Merck silica gel 60 PF254 and 60 (0.063-0.2 mm) 
were used for rotatory chromatography and column 
chromatography, respectively. Melting points were 
determined with a hot-stage apparatus and are 
uncorrected. Optical rotations were measured at the 
sodium line at ambient temperature (26 
o
C). Mass 
spectra were carried out using electrospray ionization 
techniques (ESI) or fast atom bombardment (FAB+) 
Nuclear Magnetic Resonance spectra were 
determined at 500 MHz for 
1
H NMR and 125.7 MHz 
for 
13
C NMR in the presence of tetramethylsilane 





references: CDCl3 (δH 7.26), CD3OD (δH 3.31), C6D6 
(δH 7.16); 
13
C NMR references: CDCl3 (δC 77.0), 
CD3OD (δC  49.0), C6D6 (δC 128.4). 
The amino acids H-Hyp-OMe∙HCl, H-Hyp-OH, 
Boc-Pro-OH, H-Pro-OMe∙HCl, and Boc-Leu-OH are 
commercial reagents and were purchased from 
Bachem, Fluorochem and AdvancedChemTech. 
Abbreviations: br b, broad band (in the NMR 
spectra); DIB, (diacetoxyiodo)benzene; LTA, lead 
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tetraacetate; DCM, dichloromethane; DCE 
dichloroethane; DIPEA, diisopropylethylamine; 
HBTU, O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyl 
uronium hexafluorophosphate; Hyp, hydroxyproline; 
THF, tetrahydrofuran. 
Preparation of the Substrate Precursors 
General procedure for the synthesis of 2,5-
diketopiperazines: A solution of the starting 
dipeptide (3 mmol) was treated with acetyl chloride 
(2.1 mL, 2360 mg, 30 mmol) in dry methanol (10 
mL) from 0 
o
C at 26 
o
C for 2 h. Then the solvent was 
removed under vacuum. The residue was dissolved in 
toluene (20 mL), treated with Et3N (2.1 mL, 1520 mg, 
15 mmol) and refluxed for 16 h. Then the solvent was 
removed under vacuum and the residue was purified 
by column chromatography yielding the 2,5-
diketopiperazines. 
(3S,6S)-1,6-(2R-hydroxytrimethylene)-3,4-
(trimethylene)piperazine-2,5-dione (3) Obtained 
from commercial Boc-Pro-Hyp-OMe
[23]
 (1030 mg, 3 
mmol) according to the general procedure for the 
synthesis of 2,5-diketopiperazines. The reaction 
mixture was purified by column chromatography 
(acetone/MeOH 95:5), yielding compound (3) (548 
mg, 87%), as a crystalline solid mp 109–111 ºC (from 
acetone/MeOH); []D = 127 (c 0.45, MeOH). 
1
H 
NMR (500 MHz, CD3OD): H 1.94−2.14 (m, 4H), 
2.24−2.30 (m, 2H), 3.42−3.52 (m, 3H), 3.61 (dd, J = 
4.1, 12.6 Hz, 1H), 4.38 (dd, J = 7.6, 8.5 Hz, 1H), 4.48 
(dd, J = 3.8, 3.8 Hz, 1H), 4.60 (dd, J = 6.6, 10.7 Hz, 
1H). 
13
C NMR (125.7 MHz, CD3OD): C 24.1 (CH2), 
28.7 (CH2), 37.7 (CH2), 46.2 (CH2), 54.8 (CH2), 60.2 
(CH), 61.7 (CH), 69.6 (CH), 168.7 (C), 168.8 (C). IR 





calcd for C10H15N2O3 (M
+
 + H) 211.1083, found 
211.1073. Anal. Calcd for C10H14N2O3: C, 57.13; H, 
6.71; N, 13.33. Found: C, 56.95; H, 7.09; N, 13.33. 
N-(N-tert-butoxycarbonyl-4R-benzyloxy-L-
prolyl)-4R-hydroxy-L-proline methyl ester (30), 




 1280 mg, 4 mmol) and 
4R-hydroxy-L-proline methyl ester hydrochloride (H-
Hyp-OMe•HCl, 872 mg, 4.8 mmol) in dry CH2Cl2 
(40 mL) at 0 °C, was added diisopropylethylamine 
(1.6 mL, 1.24 g, 9.6 mmol) and N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) (1.49 g, 11 mmol). The 
reaction mixture was stirred for 2 h, then was washed 
with NaHCO3 and 5% HCl, and extracted with 
CH2Cl2. The organic layer was dried on sodium 
sulfate, filtered and evaporated under vaccum. After 
purification by column chromatography 
(hexanes/EtOAc, 10:90), the dipeptide (30) was 
isolated (1.36 g, 76%) as a syrup; []D = 59 (c 0.47, 
CHCl3); 
1
H NMR (500 MHz, CD3OD): H 1.40/1.44 
(s/s, 9H), 1.93−2.05 (m, 2H), 2.22 (m, 1H), 2.42 (m, 
1H), 3.52 (m, 1H), 3.62 (m, 1H), 3.66−3.70 (m, 2H), 
3.68−3.69 (s/s, 3H), 3.74 (m, 1H), 4.22 (m, 1H), 
4.46−4.52 (m, 2H), 4.53−4.57 (m, 2H), 4.60 (dd, J = 
7.6, 7.9 Hz, 1H), 7.28 (m, 1H), 7.34 (m, 4H). 
13
C 
NMR (125.7 MHz, CD3OD): C 28.7 (3 × CH3), 
36.0/36.6 (CH2) 38.1 (CH2), 52.7/52.9 (CH3), 53.5 
(CH2), 55.8/56.0 (CH2), 58.1/58.4 (CH), 59.4/59.6 
(CH), 70.9/71.1 (CH), 72.1/72.2 (CH2), 77.8/78.5 
(CH), 81.6/81.8 (C), 128.8 (CH), 128.9 (2 × CH), 
129.5 (2 × CH), 139.5/139.6 (C), 155.9/156.3 (C), 
173.5/173.7 (C), 173.9/174.0 (C). IR (CHCl3) 
max3442, 3090, 1745, 1674, 1661, 1418 cm
–1
. 
HRMS (ESI-TOF) calcd for C23H32N2O7Na (M
+
 + 
Na) 471.2107, found 471.2107. Anal. Calcd for 
C23H32N2O7: C, 61.59; H, 7.19; N, 6.25. Found C, 
61.28; H, 7.45; N, 6.54. 
(3S,6S)-1,6-(2R-benzyloxytrimethylene)-3,4-(2R-
hydroxytrimethylene)piperazine-2,5-dione (6): 
Obtained from Boc-Hyp(Bn)-Hyp-OMe (30) (1344 
mg, 3 mmol) according to the general procedure for 
the synthesis of 2,5-diketopiperazines. The reaction 
mixture was purified by column chromatography 
(acetone), yielding compound (6) (796 mg, 84%), as 
a foam; []D = 147 (c 0.31, MeOH). 
1
H NMR (500 
MHz, CDCl3): H 2.08−2.13 (m, 2H), 2.27 (dd, J = 
6.6, 13.6 Hz, 1H), 2.50 (dd, J = 6.6, 13.6 Hz, 1H), 
3.44 (d, J = 12.6 Hz, 1H), 3.61 (m, 1H), 3.63−3.65 
(m, 2H), 4.29 (m, 1H), 4.47 (m, 1H), 4.53−4.65 (m, 
4H), 7.28 (m, 1H), 7.31−7.38 (m, 4H). 
13
C NMR 
(125.7 MHz, MeOD): C 34.9 (CH2), 37.7 (CH2), 
52.3 (CH2), 54.9 (CH2), 60.1 (CH), 60.3 (CH), 69.5 
(CH), 71.9 (CH2), 77.2 (CH), 128.8 (CH), 128.9 (2 × 
CH), 129.5 (2 × CH), 139.3 (C), 168.7 (C), 168.9 (C). 





) calcd for C17H21N2O4 (M
+
 + H) 317.1501, 
found 317.1515. Anal. Calcd for C17H20N2O4: C, 
64.54; H, 6.37; N, 8.86. Found: C, 64.41; H, 6.49; N, 
8.95. 
(3S,6S)-1,6-(2R-hydroxytrimethylene)-3-
isobutylpiperazine-2,5-dione (15): Obtained from 
commercial Boc-Leu-Hyp-OMe
[24]
 (1074 mg, 3 
mmol) according to the general procedure for the 
synthesis of 2,5-diketopiperazines. The reaction 
mixture was purified by column chromatography 
(acetone/MeOH 95:5), yielding compound (15) (529 
mg, 78%), as a crystalline solid mp 190–191 ºC (from 
acetone/MeOH); []D= 132 (c 0.21, MeOH). 
1
H 
NMR (500 MHz, CD3OD): H 0.94−0.96 (m, 6H), 
1.51 (m, 1H), 1.85−1.94 (m, 2H), 2.08 (m, 1H), 2.27 
(dd, J = 6.6, 13.2 Hz, 1H), 3.43 (d, J = 13 Hz, 1H), 
3.65 (dd, J = 4.4, 12.9 Hz, 1H), 4.16 (m, 1H), 4.45 (m, 
1H), 4.51 (dd, J = 6.5, 11.0 Hz, 1H). 
13
C NMR (125.7 
MHz, CD3OD): C 22.2 (CH3), 23.3 (CH3), 25.8 (CH), 
38.2 (CH2), 39.4 (CH2), 54.6 (CH), 55.2 (CH2), 58.7 
(CH), 69.1 (CH), 169.0 (C), 173.0 (C). IR (CHCl3) 







 + H) 227.1396, found 227.1383. 
Anal. Calcd for C11H18N2O3: C, 58.39; H, 8.02; N, 
12.38. Found: C, 58.60; H, 7.95; N, 12.65. 
Procedure for the oxidative radical scission: 
(3S,6S)-1-acetoxymethyl-6-(2-oxoethyl)-3,4-
(trimethylene)piperazine-2,5-dione (5). A solution 
of the diketopiperazine 3 (42 mg, 0.2 mmol) in dry 
dichloroethane (4 mL) was treated with 
(diacetoxyiodo)benzene (258 mg, 0.8 mmol) and 
 7 
iodine (76 mg, 0.3 mmol), the reaction mixture was 
stirred at reflux for 20 min under irradiation with 
visible light (80 W tungsten-filament lamp). After 
cooling to 26 °C the reaction mixture was poured into 
10% aqueous Na2S2O3, and extracted with CH2Cl2. 
The organic layer was dried over sodium sulfate and 
filtered; then the solvent was removed under vacuum, 
and the residue was purified by column rotatory 
chromatography (hexane/EtOAc 20:80), yielding 
compound (5) (32 mg, 60%), as a syrup; []D = 66 
(c 0.67, CHCl3). 
1
H NMR (500 MHz, C6D6): H 1.01 
(m, 1H), 1.14 (m, 1H), 1.55 (s, 3H), 1.78 (m, 1H), 
1.88 (m, 1H), 2.58 (dd, J = 4.1, 17.3 Hz, 1H), 2.81 
(dd, J = 7.3, 17.3 Hz, 1H), 2.94 (ddd, J = 3.8, 8.8, 
12.3 Hz, 1H), 3.193.24 (m, 2H), 4.19 (dd, J = 4.4, 
6.9 Hz, 1H), 5.16 (d, J = 10.7 Hz, 1H), 5.37 (d, J = 
11.0 Hz, 1H), 9.43 (s, 1H). 
13
C NMR (125.7 MHz, 
C6D6): C 20.5 (CH3), 22.8 (CH2), 28.8 (CH2), 41.7 
(CH2), 45.9 (CH2), 55.8 (CH), 59.2 (CH), 67.7 (CH2), 
164.1 (C), 169.5 (C), 169.9 (C), 197.5 (C). IR 
(CHCl3) max 1741, 1675, 1458 cm
–1
. HRMS (ESI-
TOF) calcd for C12H16N2O5Na (M
+
 + Na) 291.0957, 
found 291.0949. Anal. Calcd for C12H16N2O5: C, 
53.73; H, 6.01; N, 10.44. Found: C, 53.93; H, 6.29; N, 
10.38. 
General procedure for the scission of 4-
hydroxyproline derivatives and reductive 
amination with secondary amines: A solution of the 
substrate 3 or 6 (0.2 mmol) in dry dichloroethane (4 
mL) was treated with (diacetoxyiodo)benzene (258 
mg, 0.8 mmol) and iodine (76 mg, 0.3 mmol). The 
reaction mixture was stirred at reflux for 20 min 
under irradiation with visible light (80 W tungsten-
filament lamp). After cooling to 26 °C the reaction 
mixture was poured into 10% aqueous Na2S2O3, and 
extracted with CH2Cl2. The organic layer was dried 
over sodium sulfate and filtered; then the solvents 
was removed under vacuum. The residue was 
dissolved in dry dichloroethane (3 mL) and treated 
with the secondary amine (0.24 mmol) and 
triethylamine (39 μL, 0.28 mmol). After 30 min at 
26 °C, sodium (triacetoxy)borohydride (127 mg, 0.6 
mmol) was added. The reaction mixture was stirred 
for 16 h before being poured into saturated aqueous 
NaHCO3 and extracted with CH2Cl2. The organic 
layer was dried over sodium sulfate and filtered; then 
the solvent was removed under vacuum, and the 




Obtained from substrate (3) [42 mg, 0.2 mmol] 
according to the general procedure for the scission of 
4-hydroxyproline derivatives and reductive amination 
with secondary amines, using dibenzylamine (46 µL, 
0.24 mmol) as the secondary amine. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (8) (45 mg, 
50%), as a syrup; []D = 70 (c 0.44, CHCl3). 
1
H 
NMR (500 MHz, CD3OD): H 1.821.90 (m, 3H), 
1.92 (s, 3H), 2.08 (m, 1H), 2.222.30 (m, 2H), 
2.432.53 (m, 2H), 3.283.40 (m, 2H), 3.50 (d, J = 
13.2 Hz, 2H), 3.58 (d, J = 13.2 Hz, 2H), 4.09 (dd, J = 
6.6, 7.9 Hz, 1H), 4.29 (dd, J = 1.9, 6.5 Hz, 1H), 5.13 
(d, J = 10.7 Hz, 1H), 5.48 (d, J = 10.7 Hz, 1H), 7.21 
(dd, J = 5.7, 6.9 Hz, 2H), 7.26−7.37 (m, 8H). 
13
C 
NMR (125.7 MHz, CD3OD): C 20.7 (CH3), 23.3 
(CH2), 26.6 (CH2), 29.5 (CH2), 46.1 (CH2), 49.7 
(CH2), 58.4 (CH), 59.6 (2 × CH2), 60.2 (CH), 68.0 
(CH2), 128.1 (2 × CH), 129.3 (4 × CH), 130.2 (4 × 
CH), 140.8 (2 × C), 166.7 (C), 171.7 (C), 171.8 (C). 





) calcd for C26H32N3O4 (M
+
 + H) 450.2393, 
found 450.2409. Anal. Calcd for C26H31N3O4: C, 




Obtained from substrate (3) [42 mg, 0.2 mmol] 
according to the general procedure for the scission of 
4-hydroxyproline derivatives and reductive amination 
with secondary amines, using morpholine (21 µL, 
0.24 mmol) as the  secondary amine. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (9) (48 mg, 
68%) as a syrup; []D = 40 (c 0.14, CHCl3). 
1
H 
NMR (500 MHz, CD3OD): H 1.902.00 (m, 2H), 
2.03 (m, 1H), 2.05 (s, 3H), 2.14 (m, 1H), 2.342.43 
(m, 6H), 2.452.55 (m, 2H), 3.47 (ddd, J = 3.5, 8.8, 
12.0 Hz, 1H), 3.653.69 (m, 5H), 4.25 (dd, J = 6.3, 
8.5 Hz, 1H), 4.40 (m, 1H), 5.39 (d, J = 10.7 Hz, 1H), 
5.68 (d, J = 10.7 Hz, 1H). 
13
C NMR (125.7 MHz, 
CD3OD): C 20.6 (CH3), 22.9 (CH2), 26.2 (CH2), 30.1 
(CH2), 46.4 (CH2), 54.9 (2 × CH2), 55.0 (CH2), 59.2 
(CH), 60.2 (CH), 67.8 (2 × CH2), 68.8 (CH2), 166.3 
(C), 171.1 (C), 171.9 (C). IR (CHCl3) max 1742, 
1667, 1449 cm
–1
. HRMS (ESI-TOF) calcd for 
C16H26N3O5 (M
+
 + H) 340.1872, found 340.1870. 
Anal. Calcd for C16H25N3O5: C, 56.62; H, 7.43; N, 
12.38. Found: C, 56.48; H, 7.55; N, 12.58. 
(3S,6S)-1-acetoxymethyl-6-(2-morpholinoethyl)-
3,4-(2R-benzyloxytrimethylene)piperazine-2,5-
dione (10): Obtained from substrate (6) [63 mg, 0.2 
mmol] according to the general procedure for the 
scission of 4-hydroxyproline derivatives and 
reductive amination with secondary amines, using 
morpholine (21 µL, 0.24 mmol) as the secondary 
amine. The reaction mixture was purified by column 
chromatography (CH2Cl2/MeOH 98:2), yielding 
compound (10) (63 mg, 71%), a yellowish syrup; 
[]D = 43 (c 0.43, CHCl3). 
1
H NMR (500 MHz, 
CD3OD): H 2.00 (m, 1H), 2.04 (m, 3H), 2.14 (m, 
1H), 2.362.43 (m, 5H), 2.442.50 (m, 2H), 2.56 (dd, 
J = 6.0, 13.2 Hz, 1H), 3.56 (d, J = 13.2 Hz, 1H), 3.63 
(dd, J = 4.4, 4.4 Hz, 4H), 3.85 (dd, J = 5.0, 13.2 Hz, 
1H), 4.28 (dd, J = 4.7, 4.7 Hz, 1H), 4.41 (m, 1H), 
4.48 (dd, J = 6.0, 11.4 Hz, 1H), 4.54 (d, J = 11.7 Hz, 
1H), 4.58 (d, J = 11.7 Hz, 1H), 5.37 (d, J = 10.7 Hz, 
1H), 5.69 (d, J = 10.7 Hz, 1H), 7.27 (m, 1H), 
7.317.38 (m, 4H). 
13
C NMR (125.7 MHz, CD3OD): 
C 20.7 (CH3), 26.1 (CH2), 36.4 (CH2), 53.3 (CH2), 
54.8 (2 × CH2), 55.0 (CH2), 58.6 (CH), 59.0 (CH), 
67.7 (2 × CH2), 68.7 (CH), 72.0 (CH2), 76.3 (CH2), 
128.8 (CH), 128.9 (2 × CH), 129.5 (2 × CH), 139.3 
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(C), 166.3 (C), 171.3 (C), 171.9 (C). IR (CHCl3) 







 + H) 446.2291, found 446.2279. 
Anal. Calcd for C23H31N3O6: C, 62.01; H, 7.01; N, 
9.43. Found: C, 61.91; H, 7.21; N, 9.16. 
(3S,6S)-1-acetoxymethyl-6-(2-[4R-hydroxy-2S-
methoxycarbonylpyrrolidinyl]ethyl)-3,4-
(trimethylene)piperazine-2,5-dione (11): Obtained 
from substrate (3) [42 mg, 0.2 mmol] according to the 
general procedure for the scission of 4-
hydroxyproline derivatives and reductive amination 
with secondary amines, using H-Hyp-OMe·HCl (44 
mg, 0.24 mmol) as the secondary amine. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (11) (52 
mg, 65%) as a syrup; []D = 5 (c 0.15, MeOH). 
1
H 
NMR (500 MHz, CDCl3): H 1.852.03 (m, 3H), 2.06 
(s, 3H), 2.122.24 (m, 2H), 2.312.42 (m, 3H), 2.58 
(dd, J = 4.1, 10.1 Hz, 1H), 2.65 (m, 1H), 2.92 (m, 1H), 
3.26 (d, J = 9.8 Hz, 1H), 3.34 (dd, J = 4.4, 9.8 Hz, 
1H), 3.49 (ddd, J = 3.8, 9.1, 12.3 Hz, 1H), 3.65 (m, 
1H), 3.70 (s, 3H), 4.14 (dd, J = 7.6, 8.5 Hz, 1H), 4.28 
(m, 1H), 4.38 (br d, J = 6.3 Hz, 1H), 5.23 (d, J = 10.7 
Hz, 1H), 5.82 (d, J = 10.7 Hz, 1H). 
13
C NMR (125.7 
MHz, CDCl3): C 20.8 (CH3), 22.4 (CH2), 26.0 (CH2), 
28.4 (CH2), 38.9 (CH2), 45.5 (CH2), 49.8 (CH2), 52.3 
(CH2), 56.5 (CH3), 59.1 (CH), 62.0 (CH), 64.1 (CH), 
66.9 (CH), 70.3 (CH2), 164.8 (C), 169.9 (C), 170.3 





) calcd for C18H28N3O7 (M
+
 
+ H) 398.1927, found 398.1944. Anal. Calcd for 
C18H27N3O7: C, 54.40; H, 6.85; N, 10.57. Found: C, 




Obtained from substrate (6) [63 mg, 0.2 mmol] 
according to the general procedure for the scission of 
4-hydroxyproline derivatives and reductive amination 
with secondary amines, using H-Pro-OMe·HCl (58 
mg, 0.24 mmol) as the secondary amine. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (12) (57 
mg, 59%) as a yellowish syrup; []D = 68 (c 0.20, 
CHCl3). 
1
H NMR (500 MHz, CD3OD): H 1.781.92 
(m, 3H), 2.04 (m, 1H), 2.06 (s, 3H), 2.14 (m, 1H), 
2.20 (m, 1H), 2.342.43 (m, 3H), 2.55 (dd, J = 6.0, 
13.2 Hz, 1H), 2.76 (m, 1H), 3.13 (m, 1H), 3.20 (m, 
1H), 3.57 (d, J = 13.2 Hz, 1H) 3.69 (s, 3H), 3.78 (dd, 
J = 5.0, 13.2 Hz, 1H), 4.26 (dd, J = 4.4, 4.7 Hz, 1H), 
4.434.50 (m, 2H), 4.54 (d, J = 11.7 Hz, 1H), 4.58 (d, 
J = 11.7 Hz, 1H), 5.37 (d, J = 10.7 Hz, 1H), 5.70 (d, J 
= 10.7 Hz, 1H), 7.27 (m, 1H), 7.317.37 (m, 4H). 
13
C 
NMR (125.7 MHz, CD3OD): C 20.7 (CH3), 23.9 
(CH2), 27.9 (CH2), 30.0 (CH2), 36.2 (CH2), 50.9 
(CH2), 52.3 (CH3), 53.1 (CH2), 54.2 (CH2), 58.6 (CH), 
59.0 (CH), 67.0 (CH), 68.7 (CH2), 71.9 (CH), 76.3 
(CH2), 128.8 (CH), 128.9 (2 × CH), 129.4 (2 × CH), 
139.3 (C), 166.3 (C), 171.5 (C), 171.9 (C), 175.7 (C). 
IR (CHCl3) max 3066, 1741, 1673, 1456, 1438 cm
–1
. 
HRMS (ESI-TOF) calcd for C25H33N3O7Na (M
+
 + 
Na) 510.2216, found 510.2215. Anal. Calcd for 
C25H33N3O7: C, 61.59; H, 6.82; N, 8.62. Found: C, 
61.88; H, 7.16; N, 8.62. 
Procedure for the scission of 4-hydroxyproline 
derivatives and reduction process: A solution of the 
substrate (3) [42 mg, 0.2 mmol] in dry dichloroethane 
(4 mL) was treated with (diacetoxyiodo)benzene 
(258.0 mg, 0.8 mmol) and iodine (76.0 mg, 0.3 
mmol). The reaction mixture was stirred at reflux for 
20 min under irradiation with visible light (80 W 
tungsten-filament lamp). After cooling to 26 °C the 
reaction mixture was poured into 10% aqueous 
Na2S2O3, and extracted with CH2Cl2. The organic 
layer was dried over sodium sulfate and filtered; then 
the solvent was removed under vacuum. The residue 
was dissolved in dry methanol (2 mL) and sodium 
borohydride (11 mg, 0.3 mmol) was added. The 
reaction mixture was stirred for 16 h, before 
removing the solvent under vacuum. The residue was 
purified by rotatory chromatography (CH2Cl2/MeOH 
98:2), to afford the alcohols (13, 20 mg, 42%) and 
(14, 9 mg, 24%). 
(3S,6S)-1-methoxymethyl-6-(2-hydroxyethyl)-
3,4-(trimethylene)piperazine-2,5-dione (13): as a 
syrup; []D = 49 (c 0.38, CHCl3). 
1
H NMR (500 
MHz, CD3OD): H 1.902.10 (m, 3H), 2.23 (m, 1H), 
2.312.45 (m, 2H), 3.30 (s, 3H), 3.47 (ddd, J = 3.8, 
9.1, 12.3 Hz, 1H), 3.603.70 (m, 3H), 4.284.34 (m, 
2H), 4.74 (d, J = 10.4 Hz, 1H), 5.12 (d, J = 10.4 Hz, 
1H). 
13
C NMR (125.7 MHz, CD3OD): C 23.3 (CH2), 
29.7 (CH2), 31.7 (CH2), 46.5 (CH2), 56.7 (CH3), 57.5 
(CH), 59.2 (CH2), 60.2 (CH), 74.9 (CH2), 167.6 (C), 





) calcd for C11H19N2O4 (M
+
 + H) 
243.1345, found 243.1356. Anal. Calcd for 
C11H18N2O4: C, 54.53; H, 7.49; N, 11.56. Found: C, 
54.76; H, 7.83; N, 11.32. 
(3S,6S)-6-(2-hydroxyethyl)-3,4-
(trimethylene)piperazine-2,5-dione (14): []D = 
90 (c 0.15, CHCl3). 
1
H NMR (500 MHz, CD3OD): 
H 1.841.95 (m, 2H), 1.972.05 (m, 2H), 2.23 (m, 
1H), 2.30 (m, 1H), 3.503.53 (m, 2H), 3.713.84 (m, 
2H), 4.234.26 (m, 2H). 
13
C NMR (125.7 MHz, 
CD3OD): C 23.5 (CH2), 29.1 (CH2), 33.1 (CH2), 46.5 
(CH2), 55.3 (CH), 60.18 (CH), 60.22 (CH2), 168.3 





) calcd for C9H15N2O3 (M
+
 + H) 
199.1083, found 199.1071. Anal. Calcd for 
C9H14N2O3: C, 54.53; H, 7.12; N, 14.13. Found: C, 
54.59; H, 6.95; N, 14.29. 
(3S,6S)-1-(acetoxymethyl)-6-(2-(dibenzylamino) 
ethyl)-3-isobutylpiperazine-2,5-dione (17): Formed 
from diketopiperazine (15) [45 mg, 0.2 mmol] 
according to the general procedure for the scission of 
4-hydroxyproline derivatives and reductive amination 
with secondary amines, using dibenzylamine (46 µL, 
0.24 mmol) as secondary amines. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (17) (55 
mg, 59%), as a syrup; []D = 31 (c 0.24, CHCl3). 
1
H 
NMR (500 MHz, CD3OD): H 0.91 (d, J = 6.6 Hz, 
3H), 0.93 (d, J = 6.5 Hz, 3H), 1.48 (m, 1H), 1.56 (m, 
1H), 1.74 (m, 1H), 1.98 (s, 3H), 2.06−2.10 (m, 2H), 
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2.56 (m, 1H), 2.65 (m, 1H), 3.48 (d, J = 13.6 Hz, 2H), 
3.69 (d, J = 13.6 Hz, 2H), 3.91 (dd, J = 5.0, 9.5 Hz, 
1H), 4.20 (dd, J = 5.7, 6.0 Hz, 1H), 5.06 (d, J = 10.4 
Hz, 1H), 5.22 (d, J = 10.4 Hz, 1H), 7.22 (dd, J = 7.3, 
7.3 Hz, 2H), 7.29 (dd, J = 7.3, 7.6 Hz, 4H), 7.35 (m, 
4H).
 13
C NMR (125.7 MHz, CD3OD): C 20.7 (CH3), 
21.7 (CH3), 23.5 (CH3), 25.4 (CH), 33.0 (CH2), 46.4 
(CH2), 50.5 (CH2), 54.9 (CH), 59.3 (2 × CH2), 59.9 
(CH), 70.6 (CH2), 128.2 (2 × CH), 129.4 (2 × CH), 
129.5 (2 × CH), 130.2 (4 × CH), 140.4 (2 × C), 169.8 
(C), 170.3 (C), 171.9 (C). IR (CHCl3) max 3399, 




) calcd for 
C27H36N3O4 (M
+
 + H) 466.2706, found 466.2732. 
Anal. Calcd for C27H35N3O4: C, 69.65; H, 7.58; N, 
9.03. Found: C, 69.33; H, 7.89; N, 8.77. 
(3S,6S)-1-acetoxymethyl-6-(2-morpholinoethyl)-
3-isobutylpiperazine-2,5-dione (18): Formed from 
diketopiperazine (15) [45 mg, 0.2 mmol] according to 
the general procedure for the scission of 4-
hydroxyproline derivatives and reductive amination 
with secondary amines, using morpholine (21 µL, 
0.24 mmol) as amine. The reaction mixture was 
purified by column chromatography (CH2Cl2/MeOH 
98:2), yielding compound (18) (48 mg, 68%), as a 
syrup; []D = 18 (c 0.17, CHCl3). 
1
H NMR (500 
MHz, CD3OD): H 0.97 (d, J = 6.3 Hz, 3H), 1.00 (d, J 
= 6.6 Hz, 3H), 1.64−1.72 (m, 2H), 1.83 (m, 1H), 2.07 
(s, 3H), 2.16 (m, 1H), 2.08−2.09 (m, 1H), 2.46−2.58 
(m, 6H), 3.69 (dd, J = 4.7, 4.7 Hz, 4H), 4.00 (dd, J = 
5.4, 9.1 Hz, 1H), 4.26 (dd, J = 5.4, 7.3 Hz, 1H), 5.45 
(d, J = 10.3 Hz, 1H), 5.49 (d, J = 10.3 Hz, 1H).
 13
C 
NMR (125.7 MHz, CD3OD): C 20.7 (CH3), 21.7 
(CH3), 23.5 (CH3), 25.4 (CH), 32.0 (CH2), 46.4 (CH2), 
54.6 (2 × CH2), 55.0 (CH2), 55.4 (CH), 59.7 (CH), 
67.7 (2 × CH2), 70.7 (CH2), 169.8 (C), 170.5 (C), 
172.1 (C). IR (CHCl3) max 3399, 1743, 1683, 1458 
cm
–1
. HRMS (ESI-TOF) calcd for C17H29N3O5Na (M
+
 
+ Na) 378.2005, found 378.2008. Anal. Calcd for 
C17H29N3O5: C, 57.45; H, 8.22; N, 11.82. Found: C, 
57.62; H, 8.08; N, 11.59. 
(3S,6S)-1-acetoxymethyl-6-(2-[4R-hydroxy-2S-
methoxycarbonylpyrrolidinyl]ethyl)-3-isobutyl 
piperazine-2,5-dione (19): Obtained from 
diketopiperazine (15) [45 mg, 0.2 mmol] according to 
the general procedure for the scission of 4-
hydroxyproline derivatives and reductive amination 
with secondary amines, using H-Hyp-OMe·HCl (44 
mg, 0.24 mmol) as secondary amines. The reaction 
mixture was purified by column chromatography 
(CH2Cl2/MeOH 98:2), yielding compound (19) (43 
mg, 52%), as a syrup; []D = 41 (c 0.10, MeOH). 
1
H 
NMR (500 MHz, CD3OD): H 0.96 (d, J = 6.6 Hz, 
3H), 0.99 (d, J = 6.6 Hz, 3H), 1.61−1.73 (m, 2H), 
1.83 (m, 1H), 2.00−2.14 (m, 3H), 2.07 (s, 3H), 2.40 
(dd, J = 4.1, 10.1 Hz, 1H), 2.58 (m, 1H), 2.93 (m, 1H), 
3.42 (dd, J = 5.7, 10.2 Hz, 1H), 3.51 (dd, J = 7.9, 8.2 
Hz, 1H), 3.69 (s, 3H), 3.98 (dd, J = 5.4, 9.1 Hz, 1H), 
4.27 (dd, J = 5.4, 6.9 Hz, 1H), 4.36 (m, 1H), 5.36 (d, 
J = 10.4 Hz, 1H), 5.55 (d, J = 10.4 Hz, 1H).
 13
C NMR 
(125.7 MHz, CD3OD): C 20.7 (CH3), 21.8 (CH3), 
23.5 (CH3), 25.4 (CH), 34.3 (CH2), 40.1 (CH2), 46.4 
(CH2), 52.1 (CH2), 52.4 (CH3), 55.0 (CH), 59.9 (CH2), 
62.2 (CH), 66.0 (CH), 70.6 (CH), 71.2 (CH2), 169.8 
(C), 170.5 (C), 172.1 (C) 175.5 (C). IR (CHCl3) max 
3390, 1740, 1683, 1438 cm
–1
. HRMS (ESI-TOF) 
calcd for C19H31N3O7Na (M
+
 + Na) 436.2060, found 
436.2051. Anal. Calcd for C19H31N3O7: C, 55.19; H, 
7.56; N, 10.16. Found: C, 55.59; H, 7.19; N, 10.15. 
(3S,6S)-6-(2-hydroxyethyl)-3-isobutylpiperazine 
-2,5-dione (20): Obtained from diketopiperazine (15) 
[45 mg, 0.2 mmol] according to the general 
procedure for the scission of 4-hydroxyproline 
derivatives and reduction. The reaction mixture was 
purified by rotatory chromatography (CH2Cl2/MeOH 
99:1), yielding compound (20) as an amorphous solid 
(24 mg, 57%): []D = 25 (c 0.21, MeOH). 
1
H NMR 
(500 MHz, CD3OD): H 0.95 (d, J = 6.6 Hz, 3H), 
0.97 (d, J = 6.6 Hz, 3H) 1.64 (m, 1H), 1.72 (m, 1H), 
1.84 (m, 1H), 1.91 (m, 1H), 2.12 (m, 1H), 3.713.74 
(m, 2H), 3.93 (dd, J = 4.4, 8.5 Hz, 1H), 4.05 (dd, J = 
4.7, 8.2 Hz, 1H). 
13
C NMR (125.7 MHz, CD3OD): C 
22.0 (CH3), 23.5 (CH3), 25.3 (CH), 38.3 (CH2), 45.2 
(CH2), 54.0 (CH), 54.6 (CH), 59.3 (CH2), 170.8 (C), 





) calcd for C10H19N2O3 (M
+
 + H) 
215.1396, found 215.1414. Anal. Calcd for 
C10H18N2O3: C, 56.06; H, 8.47; N, 13.07. Found: C, 
56.23; H, 8.43; N, 12.75. 
Procedure for the scission and Horner-
Wadsworth-Emmons reaction. Preparation of  
(3S,6S)-1-(acetoxymethyl)-6-(3-ethoxycarbonyl-2-
propen-1-yl)-3-isobutyl piperazine-2,5-dione (21): 
A solution of the substrate (15) [45 mg, 0.2 mmol] in 
dry dichloroethane (4 mL) was treated with 
(diacetoxyiodo)benzene (258.0 mg, 0.8 mmol) and 
iodine (76.0 mg, 0.3 mmol). The reaction mixture 
was stirred at reflux for 20 min under irradiation with 
visible light (80 W tungsten-filament lamp), and then 
was poured into 10% aqueous Na2S2O3, and extracted 
with CH2Cl2. The organic layer was dried over 
sodium sulfate and filtered; the solvent was removed 
under vacuum, to give a residue containing the 
scission product (aldehyde), which was not purified, 
but was used directly in a Horner-Wadsworth-
Emmons (HWE) reaction. 
The HWE reagent was prepared from triethyl 
phosphonoacetate (44 μL, 49.7 mg, 0.22 mmol) 
which was slowly added to a suspension of sodium 
hydride (60% in mineral oil, 9 mg, 0.22 mmol) in dry 
THF (3mL) at 20 °C, and stirred for 1 h. Then, a 
solution of the crude aldehyde in dry THF (2 mL) 
was added dropwise to the HWE reagent, and the 
mixture was stirred at 20 °C for 2 h before being 
poured into water and extracted with diethyl ether. 
The organic layer was dried, filtered and evaporated 
as usual, and the residue was purified by rotatory 
chromatography (CH2Cl2/MeOH, 99:1), yielding 
product (21) (38 mg, 54%) as a yellowish syrup; []D 
= 48 (c 0.08, CHCl3). 
1
H NMR (500 MHz, CDCl3): 
H 0.93 (d, J = 5.7 Hz, 3H), 0.96 (d, J = 6.0 Hz, 3H), 
1.27 (dd, J = 7.0, 7.3 Hz, 3H), 1.59 (m, 1H), 
1.701.80 (m, 2H), 2.09 (s, 3H), 2.82 (m, 1H), 2.92 
(m, 1H), 4.03 (m, 1H), 4.17 (ddd, J = 7.0, 7.3, 7.5 Hz, 
2H), 4.31 (dd, J = 4.7, 5.0 Hz, 1H), 5.39 (d, J = 10.4 
 10 
Hz, 1H), 5.50 (d, J = 10.4 Hz, 1H), 5.93 (d, J = 15.8 
Hz, 1H), 6.83 (ddd, J = 7.6, 7.9, 15.5 Hz, 1H), 7.38 
(br b, 1H). 
13
C NMR (125.7 MHz, CDCl3): C 14.2 
(CH3), 20.7 (CH3), 20.8 (CH3), 23.0 (CH3), 24.2 (CH), 
35.2 (CH2), 45.0 (CH2), 53.7 (CH), 59.0 (CH), 60.6 
(CH2), 68.3 (CH2), 126.4 (CH), 140.7 (CH), 165.3 
(C), 166.4 (C), 167.6 (C), 170.5 (C). IR (CHCl3) 
max 3394, 1744, 1716, 1684, 1457 cm
–1
. HRMS 
(ESI-TOF) calcd for C17H26N2O6Na (M
+
 + Na) 
377.1689, found 377.1684. Anal. Calcd for 
C17H26N2O6: C, 57.61; H, 7.39; N, 7.90. Found: C, 
57.42; H, 7.44; N, 8.17. 
Procedure for deprotection of the benzyl ether 





(23): A solution of the benzyl ether derivative, such 
as substrate 10 (67 mg, 0.15 mmol), in acetic acid 
(2.5 mL) was treated with Pd (10% on carbon, 25 
mg) and the reaction was stirred at room temperature 
and under hydrogen atmosphere (1 atm) for 16 h. 
Then the mixture was filtered through Celite and the 
solvent was removed under vacuum. The residue was 
purified by rotatory chromatography (CH2Cl2/MeOH 
96:4), yielding compounds (22, 19 mg, 36%) and (23, 
12.5 mg, 28%). When the reaction was performed 
under higher hydrogen pressure (4 atm), compound 
23 was obtained (30 mg, 67%). 
Compound (22): Syrup; []D = 51 (c 0.08, 
MeOH). 
1
H NMR (500 MHz, CDCl3): H 2.022.15 
(m, 2H), 2.05 (m, 3H), 2.372.41 (m, 6H), 2.482.55 
(m, 2H), 3.47 (d, J = 12.9 Hz, 1H), 3.603.68 (m, 
4H), 3.753.88 (m, 2H), 4.30 (d, J = 6.0 Hz, 1H), 
4.50 (m, 1H), 4.54 (dd, J = 4.1, 4.1 Hz, 1H), 5.24 (d, 
J = 10.7 Hz, 1H), 5.79 (d, J = 10.7 Hz, 1H). 
13
C NMR 
(125.7 MHz, CDCl3): 20.7 (CH3), 24.5 (CH2), 38.5 
(CH2), 53.5 (2 × CH2), 53.9 (CH2), 54.6 (CH2), 57.20 
(CH), 57.24 (CH), 66.5 (2 × CH2), 66.9 (CH), 67.8 
(CH2), 164.3 (C), 169.7 (C), 170.2 (C). IR (CHCl3) 
max 3422, 1742, 1672, 1446 cm
–1
. HRMS (ESI-
TOF) calcd for C16H26N3O6 (M
+
 + H) 356.1822, 
found 356.1819. Anal. Calcd for C16H25N3O6: C, 
54.07; H, 7.09; N, 11.82. Found: C, 54.29; H, 7.19; N, 
11.89. 
Compound (23):  Syrup; []D = 25 (c 0.39, 
MeOH). 
1
H NMR (500 MHz, CD3OD): H 1.90 (ddd, 
J = 4.4, 12.3, 12.6 Hz, 1H), 2.09 (m, 1H), 2.232.28 
(m, 2H), 2.282.35 (m, 3H), 2.422.54 (m, 3H), 2.99 
(s, 3H), 3.32 (d, J = 13.2 Hz, 1H), 3.583.66 (m, 4H), 
3.95 (dd, J = 5.4, 13.2 Hz, 1H), 4.25 (m, 1H), 
4.434.48 (m, 2H). 
13
C NMR (125.7 MHz, CD3OD): 
C 26.5 (CH2), 31.8 (CH3), 40.3 (CH2), 54.6 (CH2), 
54.9 (2 × CH2), 56.0 (CH2), 58.2 (CH), 61.0 (CH), 
67.7 (2 × CH2), 68.4 (CH), 166.1 (C), 169.5 (C). IR 
(CHCl3) max 3421, 1657, 1460 cm
–1
. HRMS (ESI-
TOF) calcd for C14H24N3O4 (M
+
 + H) 298.1767, 
found 298.1761. Anal. Calcd for C14H23N3O4: C, 




piperazine-2,5-dione (24): Obtained from substrate 
6 [315 mg, 1 mmol] according to the general 
procedure for the scission of 4-hydroxyproline 
derivatives and HWE procedure, extrapolating (5-
fold) the general amounts. After work-up, the residue 
was purified by column chromatography 
(hexanes/AcOEt, 1:1), yielding product (24) (236 mg, 
53%) as a yellowish syrup; []D = 63 (c 0.42, 
CHCl3). 
1
H NMR (500 MHz, CDCl3): H 1.26 (dd, J 
= 7.0, 7.3 Hz, 3H), 2.03 (m, 1H), 2.07 (s, 3H), 2.64 
(dd, J = 6.0, 13.6 Hz, 1H), 2.94 (m, 1H), 3.17 (m, 1H), 
3.68 (d, J = 13.2 Hz, 1H), 3.83 (dd, J = 5.0, 13.6 Hz, 
1H), 4.16 (ddd, J = 7.0, 7.0, 7.3 Hz, 2H), 4.23 (dd, J 
= 4.4, 4.4 Hz, 1H), 4.37 (m, 1H), 4.46 (ddd, J = 5.8, 
6.3, 6.7 Hz, 1H), 4.51 (d, J = 11.7 Hz, 1H), 4.55 (d, J 
= 11.7 Hz, 1H), 5.22 (d, J = 10.7 Hz, 1H), 5.77 (d, J 
= 10.7 Hz, 1H), 5.96 (d, J = 15.8 Hz, 1H), 6.77 (m, 
1H), 7.267.40 (m, 5H). 
13
C NMR (125.7 MHz, 
CDCl3): C 14.2 (CH3), 20.7 (CH3), 31.1 (CH2), 35.4 
(CH2), 52.0 (CH2), 57.4 (CH), 58.1 (CH), 60.5 (CH2), 
67.0 (CH), 71.0 (CH2), 74.7 (CH2), 125.3 (CH), 127.7 
(2 × CH), 128.0 (CH), 128.6 (2 × CH), 137.2 (C), 
142.1 (CH), 163.1 (C), 165.7 (C), 169.3 (C), 170.3 
(C). IR (CHCl3) max 3090, 3066, 1742, 1710, 1676, 
1456 cm
–1
. HRMS (ESI-TOF) calcd for 
C23H28N2O7Na (M
+
 + Na) 467.1794, found 467.1793. 
Anal. Calcd for C23H28N2O7: C, 62.15; H, 6.35; N, 
6.30. Found: C, 62.23; H, 6.38; N, 6.51. 
(3S,6S)-1-acetoxymethyl-6-(4-ethoxy-4-oxo-2-
butenyl)-3,4-(2R-hydroxytrimethylene)piperazine-
2,5-dione (25) and (3S,6S)-1-methyl-6-(4-ethoxy-4-
oxo-2-butenyl)-3,4-(2R-hydroxytrimethylene) 
piperazine-2,5-dione (26): Obtained from 
diketopiperazine (24) (222 mg, 0.5 mmol) according 
to the general procedure for deprotection of benzyl 
ether in diketopiperazines, extrapolating (3.3-fold) 
the general amounts. The reaction mixture was 
purified by rotatory chromatography (CH2Cl2/MeOH 
98:2), yielding compound 25 (77 mg, 43%) and 
compound 26 (39 mg, 26%). 
Compound 25: Syrup; []D = 83 (c 0.20, CHCl3). 
1
H NMR (500 MHz, CD3OD): H 1.23 (dd, J = 6.9, 
7.3 Hz, 3H), 1.47 (m, 1H), 1.62 (m, 1H), 1.992.09 
(m, 2H), 2.05 (s, 3H), 2.16 (m, 1H), 2.292.44 (m, 
3H), 3.40 (d, J = 12.9 Hz, 1H), 3.82 (dd, J = 4.7, 12.9 
Hz, 1H), 4.11 (ddd, J = 6.9, 6.9, 7.0 Hz, 2H), 4.41 (m, 
1H), 4.46 (m, 1H), 4.52 (dd, J = 6.0, 11.4 Hz, 1H), 
5.39 (d, J = 10.4 Hz, 1H), 5.70 (d, J = 10.7 Hz, 1H). 
13
C NMR (125.7 MHz, CD3OD): C 14.5 (CH3), 20.4 
(CH3), 20.6 (CH2), 28.9 (CH2), 34.5 (CH2), 39.4 
(CH2), 55.5 (CH2), 58.4 (CH), 60.3 (CH), 61.6 (CH), 
68.5 (CH2), 68.6 (CH2), 166.3 (C), 171.6 (C), 171.9 
(C), 174.9 (C). IR (CHCl3) max 3456, 1732, 1672, 
1575, 1447 cm
–1
. HRMS (ESI-TOF) calcd for 
C16H24N2O7Na (M
+
 + Na) 379.1481, found 379.1487. 
Anal. Calcd for C16H24N2O7: C, 53.93; H, 6.79; N, 
7.86. Found: C, 53.92; H, 6.88; N, 7.76. 
Compound 26: Syrup; []D = 58 (c 0.20, CHCl3). 
1
H NMR (500 MHz, CD3OD): H 1.23 (dd, J = 6.9, 
7.3 Hz, 3H), 1.32 (m, 1H), 1.45 (m, 1H), 1.95 (ddd, J 
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= 4.7, 12.3, 12.6 Hz, 1H), 2.03 (m, 1H), 2.16 (m, 1H), 
2.292.42 (m, 3H), 2.99 (s, 3H), 3.33 (d, J = 12.9 Hz, 
1H), 3.91 (dd, J = 5.4, 13.3 Hz, 1H), 4.10 (ddd, J = 
6.9, 7.0, 7.3 Hz, 2H), 4.24 (m, 1H), 4.434.49 (m, 
2H). 
13
C NMR (125.7 MHz, CD3OD): C 14.5 (CH3), 
19.7 (CH2), 29.7 (CH2), 31.5 (CH3), 34.3 (CH2), 40.4 
(CH2), 55.7 (CH2), 58.1 (CH), 61.5 (CH2), 62.3 (CH), 
68.3 (CH), 166.1 (C), 169.6 (C), 174.8 (C). IR 
(CHCl3) max 3450, 1727, 1660, 1449 cm
–1
. HRMS 
(ESI-TOF) calcd for C14H22N2O5Na (M
+
 + Na) 
321.1426, found 321.1425. Anal. Calcd for 
C14H22N2O5: C, 56.36; H, 7.43; N, 9.39. Found: C, 
56.11; H, 7.58; N, 9.20. 
(3S,6S)-1,4-diacetoxymethyl-6-(4-ethoxy-4-oxo-
2-butenyl)-3,4-(2-morpholinoethyl)piperazine-2,5-
dione (27): Obtained from diketopiperazine (25) (71 
mg, 0.2 mmol) according to the general procedure for 
the scission of 4-hydroxyproline derivatives and 
reductive amination with secondary amines, using 
morpholine (21 µL, 0.24 mmol) as the secondary 
amine. The reaction mixture was purified by rotatory 
chromatography (CH2Cl2/MeOH 99:1), yielding 
compound 27 (49 mg, 50%), a syrup; []D = 31 (c 
0.34, CHCl3). 
1
H NMR (500 MHz, CDCl3): H 1.23 
(dd, J = 7.0, 7.3 Hz, 3H), 1.74 (m, 1H), 1.83 (m, 1H), 
1.89 (m, 1H), 1.99 (m, 1H), 2.052.18 (m, 2H), 2.08 
(s, 6H), 2.35 (ddd, J = 2.5, 6.9, 6.9 Hz, 2H), 
2.462.70 (m, 6H), 3.683.78 (m, 4H), 4.11 (ddd, J = 
7.0, 7.3, 7.3 Hz, 2H), 4.14 (dd, J = 5.0, 8.5 Hz, 1H), 
4.32 (dd, J = 6.6, 6.6 Hz, 1H), 5.31 (d, J = 10.4 Hz, 
1H), 5.39 (d, J = 10.0 Hz, 1H), 5.52 (d, J = 10.4 Hz, 
2H). 
13
C NMR (125.7 MHz, CDCl3): C 14.2 (CH3), 
20.76 (CH3), 20.79 (CH2), 21.2 (CH3), 31.4 (CH2), 
33.2 (CH2), 33.5 (CH2), 53.2 (2 × CH2), 54.3 (CH2), 
57.7 (CH), 60.0 (CH), 60.5 (CH2), 66.4 (2 × CH2), 
68.3 (CH2), 68.6 (CH2), 166.7 (C), 167.2 (C), 170.4 
(C), 170.5 (C), 172.7 (C). IR (CHCl3) max 1713, 
1418, 1364 cm
–1
. HRMS (ESI-TOF) calcd for 
C22H35N3O9Na (M
+
 + Na) 508.2271, found 508.2272. 
Anal. Calcd for C22H35N3O9: C, 54.42; H, 7.27; N, 
8.65. Found: C, 54.42; H, 7.15; N, 8.41.  
(3S,6S)-1-methyl-4-acetoxymethyl-6-(4-ethoxy-
4-oxo-2-butenyl)-3,4-(2-morpholinoethyl)-
piperazine-2,5-dione (28): Obtained from 
diketopirazine 26 (30 mg, 0.1 mmol) according to the 
general procedure for the scission of 4-
hydroxyproline derivatives and reductive amination 
with secondary amines, using morpholine as the 
secondary amine (reducing the general amounts by 
half). The reaction mixture was purified by rotatory 
chromatography (CH2Cl2/MeOH 99:1), yielding 
compound 28 (22 mg, 52%), a syrup; []D = 19 (c 
0.40, CHCl3). 
1
H NMR (500 MHz, CD3OD): H 1.23 
(dd, J = 6.9, 7.3 Hz, 3H), 1.69 (m, 1H), 1.751.89 (m, 
2H), 1.962.16 (m, 3H), 2.06 (s, 3H), 2.39 (ddd, J = 
6.9, 7.3, 7.3 Hz, 2H), 2.452.58 (m, 6H), 2.97 (s, 3H), 
3.653.74 (m, 4H), 4.02 (dd, J = 4.7, 8.2 Hz, 1H), 
4.11 (ddd, J = 7.0, 7.3, 7.3 Hz, 2H), 4.29 (dd, J = 5.7, 
7.3 Hz, 1H), 5.45 (d, J = 10.4 Hz, 1H), 5.49 (d, J = 
10.1 Hz, 1H). 
13
C NMR (125.7 MHz, CD3OD): C 
14.6 (CH3), 20.7 (CH3), 22.4 (CH2), 32.5 (CH2), 33.2 
(CH3), 33.4 (CH2), 34.2 (CH2), 54.6 (2 × CH2), 55.7 
(CH2), 59.6 (CH), 61.5 (CH2), 63.3 (CH), 67.7 (2 × 
CH2), 70.4 (CH2), 168.2 (C), 169.1 (C), 172.1 (C), 
174.7 (C). IR (CHCl3) max 1733, 1711, 1670, 1458 
cm
–1
. HRMS (ESI-TOF) calcd for C20H33N3O7Na (M
+
 
+ Na) 450.2216, found 450.2213. Anal. Calcd for 
C20H33N3O7: C, 56.19; H, 7.78; N, 9.83. Found: C, 
56.29; H, 7.82; N, 9.52. 
(3S,6S)-1,4-di(3-butenyl)-6-(4-ethoxy-4-oxo-2-
butenyl)-3,4-(2-morpholinoethyl)-piperazine-2,5-
dione (29): A solution of the diketopiperazine 27 (48 
mg, 0.1 mmol) in dry MeCN (2 mL) was cooled to 0 
ºC and treated with allyltrimethylsilane (159 L, 1.0 
mmol) and TMS-OTf (72 μL, 0.4 mmol). The 
reaction mixture was stirred for 16 h, and then was 
poured into saturated aqueous NaHCO3 and extracted 
with EtOAc. The organic layer was dried and the 
solvent was removed as usual. The residue was 
purified by rotatory chromatography on silica gel 
(EtOAc), yielding compound (29) (30 mg, 67%), as a 
syrup; []D = 10 (c 0.27, CHCl3). 
1
H NMR (500 
MHz, CDCl3): H 1.23 (dd, J = 7.1, 7.3 Hz, 3H), 1.68 
(m, 1H), 1.751.87 (m, 2H), 1.912.05 (m, 2H), 2.10 
(m, 1H), 2.272.34 (m, 2H), 2.362.42 (m, 4H), 2.66 
(br b, 4H), 2.70 (dd, J = 7.3, 7.3 Hz, 2H), 2.993.08 
(m, 2H), 3.72 (dd, J = 4.6, 4.6 Hz, 4H), 3.843.93 (m, 
2H), 3.94 (dd, J = 4.7, 8.4 Hz, 1H), 4.07 (dd, J = 4.9, 
8.4 Hz, 1H), 4.09 (d, J = 7.1 Hz, 1H), 4.12 (d, J = 7.1 
Hz, 1H), 5.015.09 (m, 4H), 5.745.83 (m, 2H). 
13
C 
NMR (125.7 MHz, CDCl3): C 14.5 (CH3), 22.5 
(CH2), 31.7 (CH2), 32.5 (CH2), 32.6 (CH2), 34.0 
(CH2), 34.2 (CH2), 45.5 (CH2), 45.7 (CH2), 54.4 (2 × 
CH2), 56.0 (CH2), 59.5 (CH), 61.5 (CH2), 61.7 (CH), 
67.3 (2 × CH2), 117.8 (2 × CH2), 136.0 (2 ×CH), 
168.2 (C), 168.4 (C), 174.8 (C). IR (CHCl3) max 
1725, 1655, 1472 cm
–1
. HRMS (ESI-TOF) calcd for 
C24H39N3O5Na (M
+
 + Na) 472.2787, found 472.2794. 
Anal. Calcd for C24H39N3O5: C, 64.12; H, 8.74; N, 
9.35. Found: C, 64.49; H, 8.99; N, 9.70. 
Acknowledgements 
This work was partly financed by project APOGEO (Cooperation 
Program INTERREG-MAC 2014-2020, with European Funds for 
Regional Development-FEDER) and by projects SAF-2013-
48399-R, Plan Estatal I+D-RETOS (MINECO-MCIU)-European 
Social Funds (ESF) and CONACYT 2015-01-807 (CONACYT-
Mexico). C. J. S. was recipient of a postdoctoral contract from 
the Torres Quevedo Programme (PTQ15-07923) by 
MINECO/Min. Science and Innovation, cofinanced by 
BIOSIGMA SL. Finally, I.R-E. and F.C. thank CONACYT-
Mexico for Catedra contract 942 and predoctoral grant 305283 
respectively. 
References 
[1] a) For general overviews of customizable units, see: I. 
Romero-Estudillo, A. Boto, J. Org. Chem. 2015, 80, 
9379−9391; b) C. J. Saavedra, D. Hernández, A. Boto, 
Chem. Eur. J. 2018, 24, 599−607 and references cited 
therein. 
[2] a) For a review on site-selective peptide modification, 
see: J. N. deGruyter, L. R Malins, P. S. Baran, 
 12 
Biochemistry 2017, 56, 3863–3873; b) For other 
selected examples, see: T. J. Osberger, D. C. Rogness, 
J. T. Kohrt, A. F. Stepan, M. C. White. Nature 2016, 
537, 214–219; c) U. Kazmaier, A. Bayer, J. Deska, 
Synthesis 2013, 45, 1462–1468; d) I. Romero-Estudillo, 
A. Boto, Org. Lett. 2013, 15, 5778–5781 and references 
cited therein. 
[3] a) P. D. Jadhav, J. Shen, R. Sammynaiken, M. J. T. 
Reaney, Chem. Eur. J. 2015, 21, 17023−17034; b) D. 
Schumacher, C. P. R. Hackenberger, Curr. Opin. 
Chem. Biol. 2014, 22, 62–69 and references cited 
therein. 
[4] a) For reviews on DKPs, see: A. D. Borthwick, Chem. 
Rev. 2012, 112, 3641–3716; b) N. Canu, M. Moutiez, P. 
Belin, M. Gondry, Nat. Prod. Rep. 2020, 37, 312–321; 
c) P. Borgman, R. D. Lopez, A. L. Lane, Org. Biomol. 
Chem. 2019, 17, 2305–2314; d) M. B. Martins, I. 
Carvalho, Tetrahedron 2007, 63, 9923–9932; e) C. J. 
Dinsmore, D. C. Beshore, Tetrahedron 2002, 58, 3297–
3312. 
[5] a) For an example of the formation of a highly strained 
macrocycle in Herqulines B/C, where the DKP N-
substituents forced a close proximity of the Cα-lateral 
chains, see: X. Zhu, C. C. McAtee, C. S. Schindler, J. 
Am. Chem. Soc. 2019, 141, 3409–3413; b) DKP 
scaffolds for inducing turns: L. Vahdati, R. Fanelli, G. 
Bernadat, I. Correia, O. Lequin, S. Ongeri, U. Piarulli, 
New J. Chem. 2015, 39, 3250–3258.  
[6] a) For conformational studies of N-substituted DKPs, 
see: M. Budesinsky, I. Cisarova, J. Podlaha, F. 
Borremans, J. C. Martins, M. Waroquierd, E. Pauwelsd, 
Acta Cryst. 2010, B66, 662–677; b) M. Stucchi, S. 
Cairati, R. Cetin-Atalay, M. Christodoulou, G. 
Grazioso, G. Pescitelli, A. Silvani, D. C. Yildirime, G. 
Lesma, Org. Biomol. Chem. 2015, 13, 4993–5005. 
[7] a) For examples of DKP scaffolds in oligomers and 
polymers, see: peptoids, S. Suwal, T. Kodadek, Org. 
Biomol. Chem. 2014, 12, 5831–5834; b) R. Oliva, M. A. 
Ortenzi, A. Salvini, A. Papacchinia, D. Giomia, RSC 
Adv. 2017, 7, 12054–12062; c) Polyethers: Ö. Tezgel, S. 
Noinville, V. Bennevault, N. Illy, P. Guégan, Polym. 
Chem. 2019, 10, 776–785 and references cited therein. 
[8] DKP-containing polymers for DNA delivery: C. 
Madhu, C. Voshavar, K. Rajasekhar, T. Govindaraju, 
Org. Biomol. Chem. 2017, 15, 3170–3174.  
[9] a) For ligation of biomolecules or probes: A. Borbely, 
E. Figueras, A. Martins, L. Bodero, A. Raposo Moreira 
Dias, P. Lopez Rivas, A. Pina, D. Arosio, P. Gallinari, 
M. Frese, C. Steinkuhler, C. Gennari, U. Piarulli, N. 
Sewald, ChemistryOpen 2019, 8, 737–742; b) K. Tao, 
Y. Chen, A. A. Orr, Z. Tian, P. Makam, S. Gilead, M. 
Si, S. Rencus-Lazar, S. Qu, M. Zhang, P. Tamamis, E. 
Gazit, Adv. Funct. Mater. 2020, 30, 1909614; c) E. 
Dufour, L. Moni, L. Bonnat, S. Chierici, J. Garcia, Org. 
Biomol. Chem. 2014, 12, 4964–4974.  
[10] a) The Road from Host-Defense Peptides to a New 
Generation of Antimicrobial Drugs A. Boto, J. M. 
Pérez de la Lastra, C. C. González, Molecules 2018, 23, 
311–337; b) Handbook of Biologically Active Peptides, 
Ed.: A. J. Kastin, Academic Press, San Diego, 2006; 
Chapters 10 (systemins), 11 (defensins), 12 
(cathelicidins), 45 (dermaseptins), 46 (temporins); c) E. 
Montesinos, E. Bardají, Chem. Biodivers. 2008, 5, 
1225–1237. 
[11] a) J. Isaksson, B. O.Brandsdal, M. Engqvist, G. E. 
Flaten, J. S. M. Svendsen, W. Stensen, J. Med. Chem. 
2011, 54, 5786–5795; b) J. Svenson, W. Stensen, B.-O. 
Brandsdal, B. E. Haug, J. Monrad, J. S. Svendsen, 
Biochemistry 2008, 47, 3777–3788. 
[12] DKP in antimicrobials: a) S. Rajput, K. J. McLean, H. 
Poddar, I. R. Selvam, G. Nagalingam, J. A. Triccas, C. 
W. Levy, A. W. Munro, C. A. Hutton, J. Med. Chem. 
2019, 62, 9792−9805; b) H. Baia, P. Cuib, C. Zangb, S. 
Lia, Bioorg. Med. Chem. Lett. 2019, 29, 126718; c) P. 
Zhao, Y. Xue, W. Gao, J. Li, X. Zu, D. Fu, X. Bai, Y. 
Zuo, Z. Hu, F. Zhang, Peptides 2018, 101, 10–16. 
[13] a) DKP in quorum sensing inhibitors: C. Liu, H. 
Kakeya, Chem. Asian J. 2020, 15, 327−337; b) J. Zhu, 
Y. Zhang, J. Deng, H. Jiang, L. Zhuang, W. Ye, J. Ma, 
J. Jiang, L. Feng, J. Agric. Food Chem. 2019, 67, 
12013−12025; c) F. Oliveira Chagas, R. de Cassia 
Pessotti, A. M. Caraballo-Rodríguez, M. Tallarico 
Pupo, Chem. Soc. Rev. 2018, 47, 1652 − 1704 and 
references cited therein. 
[14] a) C. Labrière, N. Kondori, J. S. Caous, M. 
Boomgaren, K. Sandholm, K. N. Ekdahl, J. H. Hansen, 
J. Svenson, J Pep Sci. 2018, e3090; b) J. S. M. 
Svendsen, T. M. Grant, D. Rennison, M. A. Brimble, J. 
Svenson, Acc. Chem. Res. 2019, 52, 749−759. 
[15] a) N-methyl DKPs: P. Barbie, U. Kazmaier, Org. 
Biomol. Chem. 2016, 14, 6055–6064; b) Y. Ge, Z. Han, 
Z. Wang, K. Ding, J. Am. Chem. Soc. 2019, 141, 
8981−8988; c) L. Shi, Z. Wu, Y. Zhang, Z. Zhang, W. 
Fang, Y. Wang, Z. Wan, K. Wang, S. Ke, J. Agric. 
Food Chem. 2020, 68, 17−32. 
[16] M. Tullberg, M. Grøtli, K. Luthman, J. Org. Chem. 
2007, 72, 195–199.  
[17] a) For other DKPs with different N-substituents: X. 
Chen, X. Chen, R. R. Steimbach, T. Wu, H. Li, W. Dan, 
P. Shi, C. Cao, D. Li, A. K. Miller, Z. Qiu, J. Gao, Y. 
Zhu, Eur. J. Med. Chem. 2020, 187, 111950; b) A. 
Raposo Moreira Dias, L. Bodero, A. Martins, D. Arosio, 
S. Gazzola, L. Belvisi, L. Pignataro, C. Steinkehler, A. 
Dal Corso, C. Gennari, U. Piarulli, ChemMedChem 
2019, 14, 938–942; c) M. Faltracco, S. Cotogno, C. M. 
L. Vande Velde, E. Ruijter, J. Org. Chem. 2019, 84, 
12058−12070; d) O. Nsengiyumva, S. Hamedzadeh, J. 
McDaniel, J. Macho, G. Simpson, S. S. Panda, K. Ha, I. 
Lebedyeva, H. M. Faidallah, M. M. Al-Mohammadi, C. 
D. Hall, A. R. Katritzky, Org. Biomol. Chem., 2015, 13, 
4399–4403. 
[18] L- and D-Hyp units are commercially available.  
[19] A. Boto, J. A. Gallardo, D. Hernández, R. Hernández, 
J. Org. Chem. 2007, 72, 7260−7269 and references 
cited therein. 
 13 
[20] a) C. J. Saavedra, C. Carro, D. Hernández, A. Boto, J. 
Org. Chem. 2019, 84, 8392−8410; b) I. Romero-
Estudillo, C. J. Saavedra, A. Boto, E. Alvarez, 
Biopolymers (Pept Sci) 2015, 104, 650−662 and 
references cited therein. 
[21] Y. A. Lin, J. M. Chalker, B. G. Davis, ChemBioChem, 
2009, 10, 959−969. 
[22] Representations of structures minimized by MM2 
implemented in Chem3D Pro 15.0 (Perkin-Elmer). 
Related results were reported in reference 7. 
[23] V. Mihali, F. Foschi, M. Penso, G. Pozzi, Eur. J. Org. 
Chem. 2014, 24, 5351–5355.  
[24] R. Khan, A. Basha, R. Goverdhanam, P. C. Rao, Y. 
Tanemura, Y. Fujimoto, A. S. Begum, Bioorg. Med. 
Chem. Lett. 2015, 25, 5756–5761. 
 
 14 
FULL PAPER    
Synthesis of Diketopiperazine Scaffolds with 
tailored N- and α-chains by Selective Modification 
of Customizable Units 
 
 







b,‡,* and Alicia Boto
a,
* 
 
 
 
